ChristopherEllisCollinsMD
Rheumatology • Washington, DCLupus & Related, Rheumatoid Arthritis & Related, Spondyloarthropathy, Vasculitis
Associate Professor of Medicine, Georgetown University Medical Center Associate Program Director, Washington Hospital Center Division of Rheumatology
Dr. Collins is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
110 Irving St NW
# 2A38
Washington, DC 20010Phone+1 202-877-0333Fax+1 202-877-6130
Education & Training
National Institutes of Health Clinical CenterFellowship, Rheumatology, 2007
U Southern California2005
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Internal Medicine, 2000 - 2003- University of Southern California/Los Angeles General Medical Center (USC/LA General)Internship, Internal Medicine, 2000 - 2001
University of Arkansas For Medical Sciences College of MedicineClass of 2000
Certifications & Licensure
CA State Medical License 2001 - Present
DC State Medical License 2006 - 2020
Awards, Honors, & Recognition
- Fellow (FACR) American College of Rheumatology
Publications & Presentations
PubMed
- 5 citationsA Multianalyte Assay Panel With Cell-Bound Complement Activation Products Predicts Transition of Probable Lupus to American College of Rheumatology-Classified Lupus.Rosalind Ramsey-Goldman, Roberta Vezza Alexander, John Conklin, Cristina Arriens, Sonali Narain
ACR Open Rheumatology. 2021-02-04 - 32 citationsReal-World Effectiveness of Belimumab in the Treatment of Systemic Lupus Erythematosus: Pooled Analysis of Multi-Country Data from the OBSErve Studies.Christopher E Collins, Josefina Cortés-Hernández, Mercedes A. Garcia, Johannes von Kempis, Andreas Schwarting
Rheumatology and Therapy. 2020-11-18 - 6 citationsCell-bound complement activation products associate with lupus severity in SLE.Cristina Arriens, Roberta Vezza Alexander, Sonali Narain, Amit Saxena, Christopher E Collins
Lupus Science & Medicine. 2020-04-01
Press Mentions
Complement Activation in Patients with Probable Lupus and Ability to Predict ProgressionJanuary 16th, 2020
Osteoarthritis Risk Factors and Causes You Need to Know AboutNovember 18th, 2019- 10 Lupus Complications You Need to Know AboutJuly 24th, 2019
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
